Skincare brand Be Clinical raises ₹21 crore in seed funding
Be Clinical has raised ₹21 crore in a seed round led by Sauce, with V3 Ventures and angel investors participating. The skincare brand plans to deploy the capital toward R&D, product expansion, manufacturing capacity, team building and growth in India and new markets.
What happened
Indian skincare brand Be Clinical raised ₹21 crore in a seed round led by Sauce, with V3 Ventures and angels participating. It will use the capital for R&D,
Key facts
- ₹21 crore
Why this matters
The raise makes Be Clinical a better-capitalized emerging brand to watch for strategic partnerships in manufacturing, distribution, retail and international market entry.
What to watch
- New product and formulation launches over the next two to four quarters.
- Manufacturing expansion announcements, certifications or supply partnerships.
- Distribution additions across marketplaces, pharmacies, dermatology clinics and offline retail.
- Evidence of repeat purchase, customer reviews and sustained performance-marketing efficiency.
- International market entry, regulatory registrations or export partnerships.
- Follow-on funding or strategic partnerships indicating traction beyond seed-stage growth.
- Launch or reformulate clinically positioned products for acne, pigmentation, barrier repair and sensitive-skin use cases.
- Expand manufacturing partnerships or install additional production capacity with stronger quality assurance processes.
- Increase dermatologist, clinic, creator and performance-marketing partnerships to build trust and customer acquisition.
- Build senior R&D, operations, regulatory and growth teams.
- Test distribution in selected international markets through marketplaces, distributors or direct-to-consumer channels.